KRAS and acute myeloid leukemia: In concordance, Hamarsheh et al. identified oncogenic KRAS signaling as a driver of NLRP3 activation and reported particularly high levels of cleaved caspase-1 and increased IL-1β production in KRASmut peripheral blood mononuclear cells (PB-MNC) from AML patients compared to non-KRAS mutated PB-MNCs from AML patients [9].